ASCO GU26 special: Prof. Galsky on results of the KEYNOTE-B15 study

In this episode, UROONCO BCa chief editor Dr Benjamin Pradere (France) sits down with Matthew Galsky, Professor of Medicine at Icahn School of Medicine at Mount Sinai (New York, USA), to discuss the newly published results of the KEYNOTE-B15 trial.This marks a truly pivotal moment for muscle-invasive bladder cancer. The presentation of KEYNOTE-B15 represents one of the most practice-changing advances in localised MIBC management in recent years, opening a new era of peri-operative systemic therapy and renewed hope for our patients.KEYNOTE-B15 is a randomised phase III trial evaluating peri-operative enfortumab vedotin plus pembrolizumab in cisplatin-eligible patients with MIBC. In this in-depth discussion, Prof. Galsky walks us through the scientific rationale behind the study, the key efficacy and safety results, and crucially, how these data are likely to reshape clinical practice, not only in the immediate future but for years to come.A must-listen conversation for urologists and multidisciplinary teams involved in the care of bladder cancer patients.The KEYNOTE-B15 study will be also presented and discussed at upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study and mark your agenda! This interview was recorded at ASCO GU26. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.